Invivyd(IVVD)
NEW HAVEN, CTBiotechnology
Focus: Invivyd is a publicly traded biotechnology company focused on therapeutic antibodies for infectious diseases, headquartered in New Haven, CT. The company is in pre-revenue/early commercialization phase with a pipeline concentrated on COVID-19 monoclonal antibodies.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
38-18 this month
Cooling — net -18 jobs in 30d
5 added, 23 removed. Slower than typical.
Should You Work at Invivyd?
AI assessmentInvivyd offers early-career exposure to therapeutic antibodies and commercial-stage biotech, but cash runway and COVID-19 market headwinds present elevated execution risk.
Why Work Here
- Heavy R&D investment (541% intensity, $137M spend in FY2025) signals commitment to pipeline advancement and scientific depth
- Aggressive commercial hiring (44 of 56 active roles) indicates preparation for near-term product launches and market entry
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$25M
Pipeline & Clinical Trials
VYD222
COVID-19Clinical Trials (1)
NCT06004128Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
N/AHelp build intelligence for Invivyd
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.